Ultragenyx Pharmaceutical Inc.
UX111 (rebisufligene etisparvovec)
Sanfilippo syndrome type A (MPS IIIA)
Countdown
86days
FDA decision · ~ Sep 30, 2026 estimated
What's at stake
The FDA's approval decision on UX111 (rebisufligene etisparvovec) for Sanfilippo syndrome type A (MPS IIIA) is due ~ Sep 30, 2026. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 8-K
verified 13h ago
“a PDUFA date expected in the third quarter of 2026”